LumiraDx Ltd
lumiradx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2022 20-F, filed May 1, 2023. Its latest SEC filing is a SC 13G/A from Nov 12, 2024.
20-F for FY2022, filed May 1, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Sells diagnostic instruments, test strips and tests for healthcare systems, government organizations and national pharmacy chains.
20-F for FY2022, filed May 1, 2023
Who Were Their Customers?
It sells Instruments or places them through reagent rentals, and uses channel partners and medical wholesalers to extend access; its commercial team works with key accounts to deploy the Platform across user networks.
20-F for FY2022, filed May 1, 2023
Did Revenues Turn Into Profits?
No. It lost $447.6M in .
20-F for FY2022, filed May 1, 2023
Who Did They Compete With?
Competes with Abbott Laboratories, Becton, Dickinson, Danaher, GenMark Diagnostics, Laboratory Corporation of America Holdings, Quest Diagnostics, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Quidel, BD, Cepheid, Accelerate Diagnostics, SD Biosensor, Boditech, and Aidian
20-F for FY2022, filed May 1, 2023We primarily face competition in the IVD market from public and private companies such as Abbott Laboratories, Becton, Dickinson and…View ↗
Loading...
